Keros Therapeutics (KROS) Total Current Liabilities (2019 - 2025)

Keros Therapeutics (KROS) has 7 years of Total Current Liabilities data on file, last reported at $20.4 million in Q4 2025.

• For the quarter ending Q4 2025, Total Current Liabilities fell 25.63% year-over-year to $20.4 million; the trailing twelve-month figure through Dec 2025 stood at $20.4 million (down 25.63% YoY), and the FY2025 full-year result was $20.4 million, down 25.63% from the prior year.
• Total Current Liabilities for Q4 2025 stood at $20.4 million, down from $24.1 million in the prior quarter.
• Across five years, Total Current Liabilities topped out at $39.4 million in Q1 2025 and bottomed at $7.5 million in Q2 2021.
• The 5-year median for Total Current Liabilities is $16.6 million (2022), against an average of $19.1 million.
• Peak annual rise in Total Current Liabilities reached 110.38% in 2025, while the deepest fall reached 25.63% in 2025.
• A 5-year view of Total Current Liabilities shows it stood at $11.8 million in 2021, then jumped by 39.68% to $16.5 million in 2022, then surged by 47.3% to $24.4 million in 2023, then rose by 12.62% to $27.4 million in 2024, then slipped by 25.63% to $20.4 million in 2025.
• The last three Total Current Liabilities figures came in at $20.4 million (Q4 2025), $24.1 million (Q3 2025), and $34.7 million (Q2 2025), per Business Quant data.

Peer Comparison